Screener
Innoviva, Inc. INVA Royalty — Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Innoviva, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Innoviva, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:26 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-335235
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Revenue: | ||||
| Royalty revenue, net of amortization of capitalized fees paid of $3,456 in the three months ended June 30, 2026 and 2025, and $6,912 in the six months ended June 30, 2026 and 2025 | $56,334 | $63,880 | $111,501 | $121,687 |
| Net product sales | 51,771 | 35,493 | 93,142 | 65,772 |
| License and other revenue | 11,486 | 910 | 12,942 | 1,456 |
| Total revenue | 119,591 | 100,283 | 217,585 | 188,915 |
| Cost of products sold (inclusive of amortization of inventory fair value adjustments, excluding amortization of intangible assets) | 22,349 | 10,590 | 37,956 | 19,432 |
| Amortization of acquired intangible assets | 6,626 | 6,547 | 13,180 | 13,022 |
| Gross profit | 90,616 | 83,146 | 166,449 | 156,461 |
Item 1. Financial Statements
FAQ
- What is Innoviva, Inc.'s royalty — revenue?
- Innoviva, Inc. (INVA) reported royalty — revenue of $56.33M in Q2 2026.
- How has Innoviva, Inc.'s royalty — revenue changed year-over-year?
- Innoviva, Inc.'s royalty — revenue decreased by 11.8% year-over-year, from $63.88M to $56.33M.
- What is the long-term trend for Innoviva, Inc.'s royalty — revenue?
- Over 4 years (2021 to 2025), Innoviva, Inc.'s royalty — revenue has grown at a -11.9% compound annual growth rate (CAGR), from $391.87M to $236.48M.
- What does royalty — revenue mean?
- This represents the net income recognized from royalty-bearing assets after accounting for contract-related adjustments and excluding pass-through taxes. It serves as the primary indicator of the cash-generating capacity of the company's intellectual property portfolio. Monitoring this metric helps investors assess the performance and market demand for the underlying healthcare products licensed by the company.
Ask your AI about Innoviva, Inc.'s royalty — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude